RT Journal Article
SR Electronic
T1 Expression of Hepatocyte Growth Factor in Prostate Cancer May Indicate a Biochemical Recurrence After Radical Prostatectomy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 413
OP 418
VO 35
IS 1
A1 SACHIYO NISHIDA
A1 YOSHIHIKO HIROHASHI
A1 TOSHIHIKO TORIGOE
A1 MASANORI NOJIMA
A1 RYUTA INOUE
A1 HIROSHI KITAMURA
A1 TOSHIAKI TANAKA
A1 HIROKO ASANUMA
A1 NORIYUKI SATO
A1 NAOYA MASUMORI
YR 2015
UL http://ar.iiarjournals.org/content/35/1/413.abstract
AB We previously found that prostate cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) express hepatocyte growth factor (HGF) and that the HGF/c-MET proto-oncogene product (c-MET) signal has a role in the maintenance of prostate CSCs/CICs in an autocrine fashion. HGF is, thus, a novel marker for prostate CSCs/CICs. We hypothesized that high expression of HGF might be related to early recurrence of prostate cancer after radical prostatectomy, and the purpose of the present study was to evaluate the relationship between expression of HGF in prostate tissues and biochemical recurrence after radical prostatectomy. One hundred-one patients with prostate cancer who underwent open or laparoscopic radical prostatectomy from November 2008 to October 2011 with an adequate prostate-specific antigen (PSA) follow-up period, were investigated. Immunohistochemical staining of HGF was compared to biochemical recurrence after radical prostatectomy. Patients with tumors exhibiting HGF positivity of 5% or more had a significantly shorter biochemical recurrence-free period than that of patients whose tumor HGF positivity was less than 5% (p=0.001). In multivariate Cox regression, preoperative PSA and HGF positivity were independent predictors of biochemical recurrence following prostatectomy. Our finding suggests a direct link between expression of HGF, a novel prostate marker of CSCs/CICs, and biochemical recurrence after radical prostatectomy in patients with prostate cancer.